Aberrant regulation of the Wnt/β-catenin signaling pathway is one of the major causes of colorectal cancer (CRC). Loss-of-function mutations in APC are commonly found in CRC, leading to inappropriate activation of canonical Wnt signaling. Conversely, gain-of-function mutations in KRAS and BRAF genes are detected in up to 60% of CRCs. Whereas KRAS/mitogen-activated protein kinase (MAPK) and canonical Wnt/β-catenin pathways are critical for intestinal tumorigenesis, mechanisms integrating these two important signaling pathways during CRC development are unknown. Results herein demonstrate that transformation of normal intestinal epithelial cells (IECs) by oncogenic forms of KRAS, BRAF or MEK1 was associated with a marked increase in β-catenin/TNF4 and c-MYC promoter transcriptional activities and mRNA levels of c-Myc, Axin2 and LeF1. Notably, expression of a dominant-negative mutant of T-Cell Factor 4 (ΔTNCF4) severely attenuated IEC transformation induced by oncogenic MEK1 and markedly reduced their tumorigenic and metastatic potential in immunocompromised mice. Interestingly, the Frizzled co-receptor LRP6 was phosphorylated in a MEK-dependent manner in transformed IECs and in human CRC cell lines. Expression of LRP6 mutant in which serine/threonine residues in each particular ProlineProlineProlineSerine/ThreonineProline motif were mutated to alamines (LRP6-SA) significantly reduced β-catenin/TNF4 transcriptional activity. Accordingly, MEK inhibition in human CRC cells significantly diminished β-catenin/TNF4 transcriptional activity and c-MYC mRNA and protein levels without affecting β-catenin expression or stability. Lastly, LRP6 phosphorylation was also increased in human colorectal tumors, including adenomas, in comparison with healthy adjacent normal tissues. Our data indicate that oncogenic activation of KRAS/BRAF/MEK signaling stimulates the canonical Wnt/β-catenin pathway, which in turn promotes intestinal tumor growth and invasion. Moreover, LRP6 phosphorylation by ERK1/2 may provide a unique point of convergence between KRAS/MAPK and Wnt/β-catenin signalings during oncogenesis.

INTRODUCTION

Colorectal cancers (CRCs) develop through a series of well-characterized histopathological changes resulting from specific mutations in selected oncogenes and tumor suppressor genes. At least four sequential genetic changes need to occur to ensure CRC evolution.1 One oncogene, KRAS, as well as the tumor suppressor genes adenomatous polyposis coli (APC), SMAD4 and TP53, are the main targets of these genetic changes. Of note, mutations in the APC gene are responsible for familial adenomatous polyposis and also have a rate-limiting role in the initiation of the majority of sporadic CRCs. The major tumor suppressor function of the APC protein is a negative regulator of Wnt signaling, where it forms part of the β-catenin destruction complex, comprising Axin, GSK3β and CK1. Mutations in APC lead to β-catenin stabilization and, consequently, to the deregulation of the Wnt pathway through the activation of TCF/LEF target genes such as c-MYC.2 Most of genetically modified mice carrying different mutations in the ApC gene2 show an intestinal tumor predisposition phenotype and develop few to many adenomas. Remarkably, c-Myc deletion suppresses all the phenotypes of the ApC tumor suppressor loss and halts intestinal regeneration.4,5

KRAS is another important and frequently mutated gene during colorectal carcinogenesis. KRAS mutations are found in 35–42% of CRCs and advanced adenomas.6,7 Genetic and biochemical studies have firmly established the central role of KRAS-dependent signaling in regulating colorectal tumor cell proliferation, growth, survival, invasion and metastasis formation.7–9 The most studied KRAS effector pathways are the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)-AKT effector pathways;6,9 with inhibitors of components of both pathways currently under clinical evaluation.10–14 As KRAS and BRAF mutations are mutually exclusive in colorectal tumors,7,15,16 aberrant activation of BRAF signaling is considered critical for KRAS-mediated colorectal oncogenesis.15 BRAF relays its signals via the MAPK kinases MEK1 and MEK2, which in turn activate ERK1 and ERK2. Activated ERK1/2 then translocate into the nucleus where they phosphorylate and activate many nuclear transcription factors enhancing gene transcription.17 Studies on normal intestinal epithelial cells (IECs) in culture have demonstrated a close correlation between ERK1/2 activation and G1/S phase transition, whereas pharmacological or molecular inhibition of ERK1/2 abrogated cell proliferation.18–20 Notably, we previously localized activated forms of ERK1/2 in the nucleus of undifferentiated proliferative epithelial cells in the human intestine.18 The involvement of MEK/ERK signaling in intestinal tumorigenesis is supported by a number of observations.20 First, MEK1/2 are phosphorylated and activated in 30–40% of adenomas and 76% of colorectal tumors.21,22

1Department of Anatomy and Cell Biology, Cancer Research Pavilion, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada and 2Gastroenterology Service, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada. Correspondence: Professor N Rivard, Department of Anatomy and Cell Biology, Cancer Research Pavilion, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3201, Jean Mignault, Sherbrooke, Québec, Canada J1E4K8. E-mail: Nathalie.Rivard@USherbrooke.ca

Received 22 April 2014; revised 4 November 2014; accepted 8 November 2014; published online 15 December 2014
Second, expression of a constitutively active mutant of MEK1 or MEK2 in rodent normal IECs is sufficient to induce growth in soft agar, epithelial to mesenchymal transition (EMT) and formation of invasive metastatic tumors in nude mice. Third, synthetic MEK inhibitors inhibit intestinal polyp growth in ApcMin/+ mice and attenuate proliferation of human CRC cells in culture and in mouse xenografts. Taken together, these data strongly suggest that MEK/ERK signaling may contribute to colorectal carcinogenesis. However, the exact molecular mechanisms by which MEK/ERK signaling achieves such functions in the colon and rectum remain unclear.

Herein, we demonstrate that oncogenic activation of KRAS/BRAF/MEK signaling in IECs activates the canonical Wnt/β-catenin pathway which, in turn, promotes cell migration and invasion as well as tumor growth and metastasis. Moreover, our results indicate that MEK-dependent phosphorylation of the Frizzled co-receptor LRP6 may serve as the link between these two important signaling pathways in CRC.

RESULTS

Oncogenic KRAS and activated MEK1 induce EMT and perturb β-catenin localization

Previous reports have demonstrated that expression of constitutively active mutants of MEK1 (caMEK), BRAF or KRAS in normal IECs such as IEC-6 is sufficient to promote their transformation. As shown in Figure 1, phase-contrast microscopy confirmed that KRASG12V or caMEK-expressing IEC-6 cells had clearly lost their cell–cell contacts and exhibited a fibroblast-like appearance when compared with control cells (Figure 1a). In addition, E-cadherin protein expression was markedly down-regulated in KRASG12V and caMEK-transformed cells (Figure 1b).
suggesting that these cells have undergone an EMT, as previously detailed. As expected, treatment with the MEK inhibitor U0126 for 72 h efficiently rescued the epithelial phenotype of KRAS<sup>G12V</sup> and caMEK-expressing IEC-6 cells (Figure 1a, panels 3 and 6) and marginally increased E-cadherin expression (Figure 1b). As previously reported,<sup>23,24</sup> IEC-6 transformed by either oncogenic KRAS or caMEK did not show marked enhancement of ERK phosphorylation in comparison with control cells. One plausible explanation is that cells permanently stimulated by autoactive KRAS or MEK1 were desensitized via multiple mechanisms including the previously reported ERK-mediated feedback inhibition of MEK and possible increased basal levels of MAPK phosphatases, a phenomenon previously observed in rodent fibroblasts.<sup>79,31-33</sup>

β-Catenin links E-cadherin and α-catenin to the cytoskeleton to form a complex that maintains normal epithelial polarity and intercellular adhesion.<sup>34</sup> As E-cadherin is downregulated during EMT, we speculated that β-catenin accumulates in the cytoplasm and translocates into the nucleus in IECs transformed by oncogenic MEK (Figure 1c, panels 4–6) or KRAS (Figure 1c, panels 10–12). As shown in Figure 1c, the control cells (wtMEK, panels 1–3 or pBabe, panels 7–9) showed typical honeycomb cell surface β-catenin staining as observed in the parental IEC-6<sup>25</sup>. By contrast, after expression of activated MEK (Figure 1c, panels 4–6) or oncogenic KRAS (Figure 1c, panels 10–12), cells have changed their morphology and β-catenin decreased from cell–cell contacts, increasing in both the cytoplasm and in the nucleus (Figure 1c, panels 6 and 12).

Induction of β-catenin/TCF complex transcriptional activity in IECs transformed by oncogenic KRAS or MEK1

As nuclear β-catenin staining was observed in IECs transformed by oncogenic KRAS or activated MEK1, possible modulation of β-catenin/TCF transcriptional activity was investigated. Cells were thereby transfected with the TOPFLASH reporter, which directly assays β-catenin/TCF activity. As shown in Figure 2a, β-catenin/TCF4 transcriptional activity was significantly enhanced in cells transformed by oncogenic KRAS or MEK1 in comparison with their respective controls. Transcriptional activation of c-Myc is often used as a Wnt readout, as its promoter contains β-catenin/Tcf response elements.<sup>35</sup> Indeed, similarly to TOPFLASH activity, the c-Myc promoter activity was significantly increased in KRAS<sup>G12V</sup> and caMEK-transformed IECs (Figure 2b). Quantitative PCR (QPCR) and western blot analyses confirmed the significant MEK-dependent induction of c-Myc mRNA and protein levels in cells transformed by activated MEK1 or KRAS<sup>G12V</sup> (Figures 2c, d). Moreover, QPCR analyses demonstrated that oncogenic KRAS or MEK1 increased the expression of Axin2 and Left1 genes (Figures 2e and f), two other transcriptional targets of the β-catenin/TCF complex. These inductions were again dependent on MEK activity, as they were abrogated by U0126. These data indicate that the nuclear β-catenin/TCF complex activity is activated upon oncogenic stimulation of KRAS/MAPK signaling in IECs.

Attenuation of caMEK-driven morphological transformation of IECs occurs upon interference with the β-catenin/TCF4 complex

To test the hypothesis that the activation of the β-catenin/TCF4 complex is required for transformation induced by oncogenic KRAS/MEK signaling, a dominant-negative TCF4 mutant (∆NTCF4) was overexpressed in cells transformed by activated MEK1. This NH<sub>2</sub> terminally deleted mutant lacks the β-catenin-interaction domain and has been shown to interfere with the activity of the endogenous, constitutively active, β-catenin/TCF4 complex present in CRC cells.<sup>37,38</sup> Accordingly, caMEK-expressing cells transfected with the ∆NTCF4 construct exhibited significant attenuation of the transcriptional activity of the β-catenin/TCF complex and c-Myc promoter (Figure 3a). Furthermore, western blot analyses confirmed the reduction in c-Myc and Fra-1 transcription factors following the expression of the ∆NTCF4 mutant in caMEK cells (Figure 3b). Of note, expression of E-cadherin protein was also partially restored upon expression of the TCF4 mutant (Figure 3b). In addition, when ∆NTCF4 was expressed, the caMEK-transformed cells showed a partial reversion to an epithelial morphology (Figure 3c). Similar results were obtained after treatment of caMEK-transformed cells with ICG-001 (Figure 3d), a small-molecule antagonist of β-catenin/TCF-mediated transcription.<sup>39</sup>

Expression of ∆NTCF4 inhibits proliferative, tumoral and invasive properties of cells transformed by activated MEK1

To determine the importance of the β-catenin/TCF complex in the oncogenicity of activated MEK1 in IECs, we first assessed the proliferation rate of caMEK cells expressing or not the ∆NTCF4 mutant. As shown in Figure 4a, expression of the TCF4 mutant significantly slowed the proliferation of caMEK-transformed cells without affecting proliferation of control wtMEK-expressing cells. Furthermore, ∆NTCF4 expression strongly diminished the ability of caMEK cells to form colonies in soft agarose (Figure 4b). The effect of ∆NTCF4 expression was also determined on migration and invasion of caMEK-transformed cells in the presence of 20 μM hydroxyurea, known to arrest the cell cycle in the G1/S phase. As shown in Figures 4c and d, ∆NTCF4 expression in caMEK cells significantly reduced their capacity to migrate and to invade Matrigel. The tumorigenicity of these cell populations <i>in vivo</i> was subsequently assessed after subcutaneous injection into the flanks of nude mice. As shown in Figure 4e, caMEK-expressing cells induced palpable tumors with a short latency period of 1 week after injection. Interestingly, co-expression of ∆NTCF4 clearly impaired their capacity to grow as tumors in nude mice. Lastly, we investigated whether ∆NTCF4 expression alters the capacity of caMEK cells to form tumoral metastases in an experimental metastasis assay. Nude mice injected with caMEK cells into the tail vein showed extensive lung metastasis within 28 days, whereas caMEK cells expressing ∆NTCF4 exhibited attenuated lung colonization (Figure 4f).

Inhibition of MEK activity in human CRC cell lines significantly reduces β-catenin/TCF complex activity

To evaluate whether KRAS/MAPK signaling regulates the β-catenin/TCF complex in human cell models, we analyzed the impact of MEK inhibitor on the activity of TOPFLASH reporter activity and c-myc expression in two human CRC cell lines, namely HT-29 and DLD-1, which have an activating mutation in the BRAF and KRAS genes, respectively. As shown in Figure 5a, treatment of these CRC cell lines with U0126 significantly reduced TOPFLASH activity as well as <i>c-Myc</i> mRNA levels (Figure 5b), indicating that expression of the β-catenin/TCF complex activity was likely dependent on MEK activity in these cells. Western blot analyses demonstrated that MEK inhibition also reduced <i>c-Myc</i> protein levels in both cell lines without, however, affecting E-cadherin and β-catenin expression levels (Figure 5c).

To elucidate the molecular mechanisms by which MEK inhibition reduced β-catenin/TCF transcriptional activity in human CRC cells, β-catenin subcellular distribution was verified. As the majority of CRC cells exhibit APC mutations,<sup>40</sup> it was therefore expected that these cells would exhibit some nuclear β-catenin staining.<sup>41</sup> Indeed, control HT-29 cells showed β-catenin staining predominantly in the cytoplasm and also in the nucleus. However, the nuclear staining of β-catenin was markedly reduced upon MEK inhibition, whereas the membranous signal seemingly accumulated in areas of intercellular contacts (Figure 5d). Similar results were obtained in DLD-1 cells (data not shown). Co-immunoprecipitation assays further demonstrated that the β-catenin/TCF4 association was indeed clearly reduced following
MEK inhibition in these cells (Figure 5e). By contrast, we could not detect modified interaction of β-catenin with E-cadherin in U0126-treated cells (Figure 5f).

LRP6 is phosphorylated in a MEK-dependent manner in human CRC cells and in IECs expressing oncogenic KRAS, BRAF or MEK1. As nuclear localization of β-catenin was reduced following MEK inhibition in CRC cells, we first speculated that this could potentially be associated with changes in β-catenin phosphorylation. Indeed, CK1α phosphorylates β-catenin on serine-45, providing a recognition site for GSK3β, allowing GSK3β to phosphorylate threonine-41, serine-37 and serine-33 leading to β-catenin degradation.41 In addition, phosphorylation of β-catenin at tyrosine-142 has been shown to act as a switch from the transcriptional to the adhesive role of β-catenin.43,44 Src kinases can also phosphorylate tyrosines-86 and 654 on β-catenin; however, only tyrosine-654 phosphorylation regulates its binding to E-cadherin.45 Finally, both Akt and PKA can phosphorylate β-catenin at serine-552, which is associated with its nuclear transcriptional activity.46–48 However, by using the phospho-specific antibodies, we found that U0126 treatment did not alter β-catenin phosphorylation on these various phosphorylation sites (Figure 6a).

Upon examining the Wnt/β-catenin pathway for components that could be modulated by the MEK/ERK pathway, the Wnt coreceptor LRP6 was found to be phosphorylated on serine-1490 (S1490) and threonine-1572 (T1572) in a MEK-dependent manner (Figure 2).

**Figure 2.** Induction of β-catenin/TCF complex transcriptional activity in IECs transformed by oncogenic KRAS or MEK1. (a, b) IEC-6 cells stably expressing pBABE, KRASG12V, wtMEK or caMEK were transfected with 0.3 μg of TOPFLASH/FOPFLASH reporter genes (a) or c-myc/c-mut (4×TBE2-wt/4×TBE2-mut) luciferase reporters (b). Thirty-six hours after transfection, cells were lysed and luciferase activity was measured. The increase in luciferase activity was calculated relative to the level observed in pBABE-expressing cells, which was set at 1. Values are normalized with Renilla-luciferase vector. Results are the mean ± S.E. of at least three separate experiments. Significantly different from respective control at *p < 0.05; **p < 0.01; or ***p < 0.001 (Student’s t-test). (c, d) Cells expressing pBABE, KRASG12V, wtMEK or caMEK were treated or not with 20 μM U0126 during 24 h. Thereafter, cells were lysed and mRNA were analyzed with quantitative real-time PCR for expression of c-Myc (c) and proteins were analyzed by western blotting for the expression of c-Myc, phosphorylated ERK1/2 and total ERK2 (d). (e, f) Cells expressing pBABE, KRASG12V, wtMEK or caMEK were treated or not with 20 μM U0126 during 24 h. Thereafter, cells were lysed and mRNA analyzed with quantitative real-time PCR for expression of Axin2 and Lef1.
in both CRC cells (Figure 6b) and IECs transformed by oncogenic KRAS and MEK1 (Figure 6c). Indeed, ERK1/2 have recently been shown to activate the Wnt/β-catenin signaling via phosphorylation of LRP6 on these sites. Lrp6 phosphorylation was also markedly enhanced in IEC-6 cells transformed by the inducible BRAF:ER fusion protein (induction by 4-hydroxytamoxifen). Of note, the induction of phosphorylation was detected within 10 min following ERK activation (Figure 6d), indicating that Lrp6 phosphorylation is an early and direct event occurring following the activation of BRAF signaling. Again, treatment with MEK inhibitors, U0126 or PD184352, significantly decreased Lrp6 phosphorylation induced by oncogenic BRAF. To analyze the potential involvement of the BRAF/ERK signaling pathway in the deregulation of Lrp6 in vivo, we used BRAFCA mice carrying a Cre-activated allele of the mouse BRAF gene. These mice express normal BRAF before Cre-mediated recombination after which BRAF is expressed at physiological levels. These mice were crossed with Villin-Cre transgenic mice, expressing the transgene around embryonic day 15.5 (E15.5) only in IECs, therefore, resulting in the generation of BRAFCA mice. As shown in Figure 6e, western blot analysis of colonic epithelial enrichments showed that phosphorylation of ERK1/2 and Lrp6 was increased in BRAFCA mice in comparison with control littermates. To confirm that Lrp6 protein was directly phosphorylated by ERK1/2, we used the new specific inhibitor of ERK1/2, SCH772984. We observed that treatment with this inhibitor reduced Lrp6 phosphorylation in both IEC-6 transformed by KRAS or activated MEK1 (Supplementary Figures S1A, B and D). As expected, SCH772984 clearly inhibited ERK1/2 activity as visualized by sustained decreased phosphorylation of Fra-1, a substrate for ERK1/2. Of note, this inhibitor did not prevent long-term ERK1/2 re-phosphorylation as previously reported. We have also tested other kinase inhibitors on Lrp6 phosphorylation. Intriguingly, JNK inhibitor (SP600125) apparently decreased Lrp6 phosphorylation in KRAS-transformed cells (Supplementary Figure S1D). However, reduction in Lrp6 phosphorylation seems to be a secondary effect.

Figure 3. Attenuation of caMEK-driven morphological transformation of IECs occurs upon interference with the β-catenin/TCF4 complex. (a) Subconfluent IEC-6 wtMEK or caMEK cells stably expressing a dominant-negative form of TCF4 (ΔNTCF4) or the empty vector (EV) were transfected with 0.3 μg of the TOPFLASH/FOPFLASH reporter genes and c-myc/c-mut (4 × TBE2-wt/4 × TBE2-mut) luciferase reporters. Thirty-six hours after transfection, cells were lysed and luciferase activity was measured. The luciferase activity was calculated relative to the level observed in EV-expressing cells, which was set at 100%. Values were also normalized with Renilla-luciferase vector. Results are the mean ± s.e. of at least three separate experiments. Significantly different from respective control at *P < 0.05 or **P < 0.01 (Student’s t-test). (b) Equal amounts of lysates from IEC-6 wtMEK or caMEK cells stably expressing ΔNTCF4 or EV were separated by SDS-PAGE, and proteins analyzed by western blotting with specific antibodies against Tcf4, c-Myc, Fra-1, E-cadherin and total ERK2. (c) Representative phase-contrast microscopy images of IEC-6 caMEK expressing ΔNTCF4 or EV (as control). Bars: 50 μm. (d) Representative phase contrast microscopy images of IEC-6 caMEK that were treated or not with 7.5 μM ICG-001 during 36 h. Bars: 25 μm.
of reduced expression of Lrp6. Indeed, treatment with this inhibitor consistently reduced total Lrp6 expression in all cell lines analyzed by more than 50% as revealed by our densitometric analyses (Supplementary Figure S1D). This suggests that JNK activity may regulate Lrp6 expression (not phosphorylation). Of note, GSK3 inhibition by SB216763 did not alter Lrp6 phosphorylation nor expression (Supplementary Figure S1D).

Finally, we have verified if altered expression of secreted agonists/antagonists of Wnt signalling might be involved in the oncogenic action of the KRAS/MAPK pathway. We therefore used LGK974, an inhibitor of the Wnt-specific acyltransferase porcupine. This inhibitor blocks Wnt secretion and has been shown to potently inhibit Wnt signaling in vitro and in vivo.53,54 We used the inhibitor at 500 nM, a concentration previously described to abrogate Wnt secretion and signaling.53,54 However, treatment of caMEK-transformed cells or BRAF:ER cells (stimulated or not with tamoxifen) with LGK964 did not alter their transformed morphology nor Lrp6 phosphorylation (Supplementary Figures S2A–C). Similar results were obtained when we treated the cells with DKK-1, an extracellular antagonist of Lrp6 (Supplementary Figures S2A–C). This suggests that Wnt secretion did not contribute to induce Lrp6 phosphorylation and morphological transformation upon oncogenic activation of the BRAF/MEK/ERK pathway.

Oncogenic KRAS signaling triggers β-catenin/TCF4 complex activation via Lrp6 phosphorylation

To analyze whether MEK-dependent Lrp6 phosphorylation was responsible for the increased β-catenin/TCF4 activity observed in cells transformed by oncogenic activation of KRAS signalling, IECs transformed by oncogenic KRAS were transfected with an increasing amount of wild-type LRP6 or LRP6–5A mutant, a
mutant in which its serine/threonine residues in each particular PPPS/TP motif was replaced by alanine. As illustrated in Figure 7a, expression of wild-type LRP6 increased TOPFLASH luciferase activity in KRAS-transformed cells in a dose-dependent manner. By contrast, expression of the LRP6-5A mutant reduced TOPFLASH activity, acting in a dominant-negative manner. Similarly, LRP6-5A abrogated BRAFV600E-induced TOPFLASH activity following tamoxifen stimulation of IEC-6 cells expressing the BRAF:ER fusion protein (Figure 7b).

These results prompted us to analyze Lrp6 contribution in transformation induced by activated MEK/ERK signaling. Because anchorage-independent growth potential may correlate better with tumorigenic growth in vivo, we determined whether Lrp6 inhibition correlated with the inhibition of tumor cell growth in soft agar rather than on plastic. As shown in Figures 7c, d, Lrp6 silencing significantly inhibited anchorage-independent growth of caMEK-transformed cells.

LRP6 phosphorylation on serine-1490 and threonine-1572 is increased in colorectal tumors

MEK/ERK signaling is thought to be affected in early stages of CRC formation because of frequent mutations in KRAS or BRAF. Thus, we first verified the expression and phosphorylation status of LRP6 in human colorectal adenomas, all of which exhibit APC-inactivating mutations (exon 15) in combination with KRAS-G12D, G13D and Q61H or BRAF (V600E)-activating mutations. As shown in Figure 8a, all adenomas displayed significantly higher phosphorylation levels of LRP6 on both serine-1490 and threonine-1572 in comparison with their corresponding benign margin. Densitometric analysis confirmed the increased ratio of phosphorylated LRP6 relative to LRP6 expression (Figure 8b). Similar increase in LRP6 phosphorylation was observed in a series of adenocarcinomas (n = 53) in comparison with their corresponding normal margins (Figure 8c). Lastly, no significant association was, however, observed between increased LRP6 phosphorylation and tumor stage (Supplementary Table S1). Representative western blot analysis on eight paired adenocarcinomas at different stages is shown in Figure 8d.

**DISCUSSION**

Gain-of-function mutations in KRAS and BRAF genes are detected in up to 60% of colorectal tumors at a relatively early stage of the carcinogenic process. The nonoverlapping occurrence of BRAF and KRAS mutations suggests that aberrant BRAF downstream signaling is a critical mechanism for KRAS-mediated oncogenesis in CRC. In this regard, expression of a constitutively active
mutant of MEK1 or MEK2 in normal IECs is sufficient to induce morphological transformation, anchorage-independent growth and tumorigenicity in mice. Importantly, aberrant activation of KRAS/BRAF/MEK signaling in these cells triggers EMT characterized by the loss of epithelial polarity and expression of junctional proteins, particularly E-cadherin (Figure 1).24,29

The cadherin/catenin-based adhesion system is the major means by which epithelial cells adhere to one another.34 β-catenin, a central structural component of this adhesion complex, also acts as a transcriptional co-activator in the Wnt signaling pathway in epithelial cells.34–36 Despite this finding, there has been much speculation over whether the cadherin-bound and signal transduction pools of β-catenin are functionally interchangeable.38–41 In the present study, we show that the nuclear transcriptional activity of β-catenin was enhanced upon sustained oncogenic stimulation of normal IECs by KRAS, BRAF or MEK. Importantly, expression of a dominant-negative TCF4 mutant that inhibits β-catenin/TCF4 transactivation severely attenuated

Figure 6. LRP6 is phosphorylated in a MEK-dependent manner in human CRC cells and in IEC-6 expressing oncogenic KRAS, BRAF or MEK1. (a, b) DLD-1 and HT-29 cells were treated or not (DMSO) with 20 μM U0126 during 16 h and equal amounts of cell lysates were separated by SDS–PAGE. In a, proteins were analyzed by western blotting for expression of β-catenin phosphorylated on serine-552, tyrosine-86, tyrosine-654 and tyrosine-142 with phospho-specific antibodies. In addition, β-catenin unphosphorylated on serine-37 and threonine-41 was also analyzed by a specific antibody as well as phosphorylated ERK1/2 and total ERK2. In b, proteins were analyzed by western blotting for expression of total LRP6 and LRP6 phosphorylated on serine-1490 and threonine-1572 as well as phosphorylated ERK1/2 and total ERK2. (c) Equal amounts of lysates from IEC-6 pBABE, KRASG12V, wtMEK and caMEK expressing cells treated or not with 20 μM U0126 during 24 h were analyzed by western blotting for the expression of total ERK2, phosphorylated ERK1/2, total Lrp6 and Lrp6 phosphorylated on serine-1490 and threonine-1572. (d) IEC-6 BRAFV600E-ER cells were stimulated or not with 250 nM 4-OH tamoxifen in presence or absence of MEK inhibitors (20 μM U0126; 2 μM PD184352) at the indicated times. Proteins were analyzed by western blotting for the expression of total ERK2, phosphorylated ERK1/2, c-Myc, β-actin, total Lrp6 and Lrp6 phosphorylated on threonine-1572 or serine-1490. (e) Mucosal enrichments from 4-week-old BRafIEC-KO and control murine colons were analyzed by western blotting for the expression of phosphorylated ERK1/2 (pERK), ERK2, total Lrp6 and Lrp6 phosphorylated on threonine-1572 or serine-1490. Five mice per group were analyzed and representative western blot analysis of two mice per group is shown.
morphological transformation and tumorigenic potential induced by oncogenic MEK1. Thus, these data suggest that KRAS/MAPK signaling may utilize the Wnt/β-catenin pathway to induce transformation in IECs.

In keeping with these results, the transcriptional activity of the β-catenin/TCF complex was reduced by MEK inhibitors in human CRC cell lines, suggesting that MEK activation also potentiates Wnt signaling in CRC. Interestingly, these effects were evident despite the presence of APC mutations. This is consistent with the recent observation that Wnt signaling components are significantly enriched in KRAS-dependent CRC cells compared with KRAS-independent cells, despite both classes having comparable APC mutations. Accordingly, Horst et al. showed that forced expression of the KRAS oncogene in the Caco-2 CRC cell line leads to nuclear accumulation of β-catenin and increases Wnt activity, whereas blocking the tyrosine kinase receptor EGFR, an activator of MAPK signaling, has the converse effect. In addition, the authors observed colocalization of nuclear β-catenin and phosphorylated ERK staining in primary colon tumor xenografts. Likewise, Phelps et al. recently reported that KRAS and RAF1 oncogenes promote nuclear accumulation of β-catenin in APC-deficient cells. Overall, these studies reveal that the KRAS/MAPK pathway can regulate β-catenin signaling in human CRC cells.

Very few studies have explored the molecular mechanisms underlying the enhancement of β-catenin transcriptional activity by oncogenic RAS/MAPK signaling. Oncogenic KRAS signaling could increase the stability of β-catenin through its phosphorylation at serine 552. However, we found in CRC cells that MEK inhibition reduced β-catenin accumulation into the nucleus and its interaction with TCF4 without affecting its global expression, its phosphorylation on serine 552 (or residues 37, 41, 86, 142 and 654) or its stabilization (data not shown). On the other hand, although the downregulation of E-cadherin on the cell membrane may contribute to nuclear β-catenin accumulation upon oncogenic activation of KRAS/MAPK signaling in normal IECs (the present study), additional mechanisms must likely be involved. Indeed, data from BRAF/ER cells suggest that E-cadherin downregulation is not necessary for Wnt activation by oncogenic MAPK signaling. Indeed, activation of BRAF/ER fusion protein in IEC-6 cells induced Lrp6 phosphorylation within 10 min and β-catenin transcriptional activity (TOPFLASH) within 16–24 h without inducing concomitant downregulation of E-cadherin during this time period (data not shown). Furthermore, in human CRC cells, E-cadherin and β-catenin expression and interaction remained unaltered following MEK inhibition. Interestingly, we observed that the Frizzled co-receptor LRP6 was phosphorylated on serine-1490 and threonine-1572 in a MEK-dependent manner in human CRC cells. Furthermore, MEK-dependent phosphorylation of Lrp6 was also observed upon sustained oncogenic activation of KRAS, BRAF and MEK1 in IECs, thus providing a mechanism integrating KRAS/MAPK and canonical Wnt/β-catenin signalings during intestinal transformation. Of note, sustained activation of ERK signaling by the BRAFV600E allele in mice also resulted in increased Lrp6 phosphorylation in the colonic tissue.
epithelium. Whether this increased Lrp6 phosphorylation was associated with higher Wnt/β-catenin signaling in normal colonocytes will require further analyses. Indeed, conflicting literature exists with regard to the role of MAPK signaling in the activation of the Wnt/β-catenin pathway in normal intestinal epithelial cells. On the one hand, data from different groups have shown that the activation of the KrasG12D or BrafV637E alleles in mouse intestinal epithelium induced serrated tumorigenesis without enhancing the Wnt signaling. Wnt signaling induction was, however, found in a substantial part of BrafV637E-induced high-grade tumors. On the other hand, Carragher et al. demonstrated that crypt hyperplasia induced by the BrafV600E
allele was rapidly associated (within 3 days) with Wnt pathway activation as visualized by the accumulation of nuclear β-catenin in crypt cells. Moreover, Phelps et al.66 reported that KRas or BRAF activation is needed for the nuclear translocation of β-catenin in colonic adenoma. Therefore, nuclear translocation of β-catenin might be regarded as a potentially RAS/MAPK-controlled step in canonical Wnt signaling.71,72

Interestingly, both the serine-1490 and threonine-1572 residues are localized within the PPPS/TP motifs of the LRP6 co-receptor, motifs which are required for Wnt/β-catenin signal transduction. Indeed, removal of any of the five PPPS/TP motifs impairs Wnt signaling, whereas removal of all five motifs results in complete loss of signaling.73,74 Thus, given their importance, the PPPS/TP motifs have been represented as major site for modulation of the Wnt/β-catenin pathway by other signaling systems. In this respect, we found that expression of LRP6-5A, a mutant in which its serine/threonine residues in each particular PPPS/TP motif is replaced by alanine (LRP6-5A), markedly reduced TOPFLASH activation in KRASG12V and BRAFV600E-transformed IECs. On the other hand, we found that Lrp6 silencing significantly reduced anchorage-independent growth of caMEK-transformed cells, hence confirming the contribution of this receptor in oncogenic action of KRAS/MAPK signaling in intestinal epithelial cells. Owing to the lack of phospho-specific antibodies, we could not verify whether Lrp5 was also phosphorylated in a MEK-dependent manner. Indeed, we compared LRP5 and LRP6 amino-acid sequences and we found that the cytoplasmic domain of LRP5 also contains serine-1503 and threonine-1578, both residues localized in PPPS/TPS motifs. Therefore, we cannot exclude that the LRP5 protein is also targeted by oncogenic KRAS signaling.

Of further interest, we found increased LRP6 phosphorylation on serine-1490 and threonine-1572 in colorectal tumors. The fact that LRP6 phosphorylation was already deregulated in human adenomas strongly suggests that phosphorylation of this protein may be involved in early stages of colorectal carcinogenesis. Unfortunately, we did not detect any significant association between LRP6 phosphorylation and the presence of mutations in KRAS or BRAF in the S3 adenocarcinomas analyzed. However, a greater number of colorectal tumors needs to be analyzed in order to clearly determine whether there is a link between LRP6 phosphorylation and KRAS or BRAF mutations. Otherwise, the fact that increased phosphorylation of LRP6 was observed in tumors exhibiting wild-type KRAS and BRAF suggests that this phosphorylation may be induced by other kinases (for example, CK1 and GSK3, see below) or oncogenic pathways activated in these CRC specimens.

In presence of Wnt, LRP6 is phosphorylated within the PPPS/TP motifs by GSK3β and multiple CK1 members, providing docking sites to bind Axin1 and GSK3, thereby sequestering both proteins away from the β-catenin destruction complex.7,3,74 However, in our cell models, blockade of MEK reduced LRP6 phosphorylation and decreased β-catenin nuclear localization and transcriptional activity without affecting β-catenin expression. One could speculate that phosphorylation of LRP6 by ERK triggers a signaling cascade controlling β-catenin nuclear localization and activity, independently of Axin or the degradation complex. Such signaling cascade operating in parallel with β-catenin stabilization has recently been documented in other biological systems.75 Indeed, activation of LRP6/Rac1/JNK2 signaling has been suggested to mediate nuclear accumulation of β-catenin independently of its stabilization during canonical Wnt signaling in stromal cells from the bone marrow.75 Intriguingly, in our cell models such as KRAS-transformed IECs, JNK activity seems to control especially LRP6 expression and not phosphorylation suggesting that LRP6 can be regulated at multiple levels. Hence, the question of how MEK-dependent phosphorylation of LRP6 promotes β-catenin transcriptional activity remains unresolved and will need to be addressed in the future.

The cellular context of RAS mutations in CRC is complex. KRAS mutations usually occur early in the course of human disease, not long after APC or β-catenin mutations.1 The contribution of RAS mutations to colon carcinogenesis is therefore linked to an altered Wnt signaling pathway. Consistent with the multihit hypothesis for colon tumor development, previous reports in mice indicate that the addition of Ras mutations to Apc loss causes an increase in adenoma size, number and invasiveness in addition to promoting the expansion of cells bearing putative stem cell markers within the tumors.67,68-70 Furthermore, Phelps et al.66 observed that homozygous loss of Apc alone in the zebrafish intestine was insufficient to cause β-catenin nuclear translocation; rather, the nuclear accumulation of β-catenin, and associated proliferation, required the additional activation of Kras or Raf1 oncogenes. Interestingly, Mydb88-dependent ERK activation was shown to drive intestinal tumorogenesis in Apcmin/+;71 mice.79 However, aside from these observations, a cohort of adenomas from Familial Adenomatous Polyposis (FAP) patients was recently analyzed and nuclear β-catenin staining was observed in the vast majority of cases, whereas the presence of KRAS mutations, detected in only 10% of the adenomas, was independent of β-catenin subcellular localization.80 In addition, cells homozygous for a targeted Apc mutation, and without evidence of any additional mutations at other loci, do show constitutive Wnt activation based on reporter assay.76 Thus, although there is little doubt that oncogenic KRAS/MAPK signaling synergizes with APC mutations in tumorigenesis by fully enhancing nuclear β-catenin translocation and activity, it has still remained unclear whether sustained MAPK activation is essential for human adenoma progression (please refer to the comment of Fodde and Tomilson71,72).

In the future, it will be quite relevant to verify whether inhibiting LRP6 function can interfere with β-catenin signaling and tumoral properties of human CRC cells exhibiting APC mutation with or without KRAS or BRAF mutations. This would be a very important finding due to the frequency of such mutations in human CRC and the difficulty to target β-catenin, KRAS and BRAF.81 In this respect, the potential utility of LRP6 blocking antibodies to inhibit Wnt signaling in tumorogenesis was recently demonstrated.82 In conclusion, our study demonstrates that the Wnt/β-catenin signaling pathway acts as a novel target of MEK/ERK signaling involved in human colorectal tumorigenesis. Whereas further studies are needed to pinpoint the molecular mechanisms by which MEK-dependent LRP6 phosphorylation induces β-catenin/TCF4 activity, the present study provides a novel fundamental insight into how oncogenic KRAS/MAPK signaling controls epithelial onco genesis in the intestine.

**MATERIALS AND METHODS**

**Materials**

The antibodies against β-catenin, c-myc, phosphorylated c-jun (serine-63), anti-HA, Frat and total ERK1/2 were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Antibodies recognizing phosphorylated ERK1/2, LRP6 (serine-1490) and β-catenin (serine-552) as well as total LRP6 and TCF4 were obtained from Cell Signalling (Danvers, MA, USA). Antibodies against E-cadherin and β-catenin were from BD Pharmingen (Missisauga, ON, Canada). Antibodies recognizing β-actin, phosphorylated LRP6 (threonine-1572) and β-catenin (tyrosine-142) were purchased from Millipore (Billerica, MA, USA). Antibodies recognizing phosphorylated β-catenin (tyrosine-68 and -654) were purchased from Abcam (Toronto, ON, Canada). The MEK inhibitor U0126 was purchased from LC Laboratories (Woburn, MA, USA) and ICG-001 was purchased from AbbMere BioSciences (Kowloon, Hong Kong, China). DKK-1 was purchased from R&D Systems (Minneapolis, MN, USA). LGK974 was purchased from Adooq Bioscience (Irvine, CA, USA). The specific ERK inhibitor SCH7729846 and MEK inhibitor PD184352 were provided by Pfizer Inc. (Groton, CT, USA). For immunofluorescence, goat anti-rabbit AlexaFluor488 fluorescein isothiocyanate-labeled or goat anti-mouse AlexaFluor568-labeled secondary antibodies were from Molecular Tools.
LRP6 silencing

To silence the expression of LRP6 in caMEK cells, we used small hairpin RNA (shRNA) plasmids containing 29-mer shRNA sequence in green fluorescent protein (GFP) vector targeted against the rat Lrp6 gene expression. Non-effective 29-mer-scrambled shRNA cassette in pGFP-V-RS Vector (Origene, Rockville, MD, USA) was used as a control. GFP was used to monitor the efficiency of transfection. Lentiviruses produced in 293T cells were used for infection according to Invitrogen recommendations (ViralPower Lentiviral Expression System). Cells were infected with either control or Lrp6-shRNA lentiviruses. After selection with puromycin (1 μg/ml), cells were used for further studies.

Experiments in mice

1-Female nude CD1 nu/nu mice were purchased from Charles River (Wilmington, MA, USA). Tumor growth: 1 × 10^5 of control and experimental cells suspended in DMEM were contralaterally injected into the subcutaneous tissue of mice.24 Tumor volume was determined by external measurement according to the formula $d^3 \times D/2$. Experimental tail vein assays: The tail vein of 5-week-old mice was injected with 1 × 10^6 cells suspended in 100 μl DMEM. Animals were killed at any sign of respiratory distress or weight loss, or after 28 days post injection.24 Lungs were maintained in Bouin’s fixative for 2 days. 2-Braf mice carrying a Cre-activated allele of the murine Braf gene were kindly provided by Dr Martin McMahon (Cancer Research Institute, UCSF/Diller Family Comprehensive Cancer Center).50 Mutations were genotyped according to published protocols.50 The C57BL/6 12.4 KviCcre transgenic line (#004586) was provided by Jackson Laboratory (Bar Harbor, MA, USA). Mutations were genotyped as described previously.56 All experimental protocols were approved by the Ethics Committee for Animal Experimentation of the Université de Sherbrooke.

Human tumors

Samples of colorectal tumors and paired normal tissues (at least 10 cm from the tumor) were obtained from patients undergoing surgical resection. Patients did not receive neoadjuvant therapy. Tissues were obtained after patient’s written informed consent, according to the protocol approved by the Institutional Human Subject Review Board of the Centre Hospitalier Universitaire de Sherbrooke. All tissues were frozen in liquid nitrogen within 15 min from resection as recommended by the Canadian Tumor Repository Network (www.ctrem.ca). Paired tissues were lysed and immunoblotted as previously described.85 Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue using a FFPE DNA Isolation Kit for Cells and Tissues (Qiagen; Electron Microscopy & Histology Technologies, Rockville, MD, USA). Experimental tail vein assays were performed in either duplicate or triplicate. Typical results shown were representative of three independent experiments. Densitometric analyses were performed by using the Image J software. Results were analyzed by the Student’s t-test and were considered statistically significant at $P < 0.05$ or lower.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Guillaume Arguin and Gérald Bernatchez for technical assistance. The biobank of colorectal cancer specimens was supported by a Team grant on digestive cancer (MT-14405). Etienne Lemieux is a student scholar from the Fonds de la Recherche en Santé du Québec (FRSQ). Nathalie Rivard and Julie C Carrier are members of the FRSQ-Funded Centre de Recherche du CHUS. Nathalie Rivard is a recipient of a Canadian Research Chair in colorectal cancer and inflammatory cell signalling. This research was supported by a grant from the Canadian Institutes of Health Research to NR (MT-14405).
REFERENCES

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.
2. Gregoireff A, Clevers H. Wnt signalling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19: 877–890.
3. Taketo MM. Mouse models of gastrointestinal tumors. Cancer Sci 2006; 97: 355–364.
4. Ashton GH, Morton JP, Myant K, Phesse TJ, Williams BJ, Redd KR et al. Phosphorylation of p27 downregulation and S phase entry in intestinal cells. J Cell Physiol 2000; 184: 2230–2237.
5. Bocker MJ, Jean D, Vezina A, Rivard N. Dual role of MEK/ERK signalling in colorectal cancer: a review. Oncogene (2015) 4914–4927.
6. Aliaga JC, Deschenes C, Beaulieu JF, Calvo EL, Rivard N. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human colorectal cancer cells and induction of metastatic tumors. BMC Cancer 2008; 8: 337–3409.
7. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A et al. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc Natl Acad Sci USA 2004; 101: 12682–12687.
8. Boulou S, Koplin J, Cossart Y, Phesse TJ, Wilkins JA, Reed KR et al. Expression and activity of mitogen activated protein kinases in human colorectal cancer cells. J Cell Physiol 2005; 201: 418–434.
9. Biedermann R, Musgrove EA. The MAP kinase pathway and colorectal cancer. Curr Opin Oncol 2009; 21: 235–240.
10. Frankel G, Ross J, Clute S, Clute S, Naylor J, Hubble A et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810–816.
11. Ikonen T, Hikiba Y, Kanai F, Arakagi J, Tanaka Y, Imamura J et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 2004; 64: 3428–3435.
12. Nakanishi M, McConnell BB, Gableh AM, Biakowska AB, Sheng H, Shao J et al. Receptor tyrosine kinases activate canonical WNT/beta-catenin signalling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation. PLoS ONE 2012; 7: e35826.
13. Sembold-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810–816.
14. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. BRAF point mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Cancer Res 2002; 62: 6451–6455.
15. Taketo MM. Mouse models of gastrointestinal tumors. Springer: vol.14. Springer, Netherlands, 2010, pp 205–241.
16. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of disease progression and novel therapeutic targets. J Cell Physiol 2011; 225: 381–388.
17. Danghui D, Coulibaly DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE et al. Constitutive activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 2008; 8: 337–3409.
18. Le Bras R, Bergeron S, Durand V, Asselin C, Saucier C, Rivard N. Dual role of MEK/ERK signalling in colorectal cancer: a review. Oncogene (2015) 4914–4927.
19. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. J Pathol Oncol 2005; 32: 322–327.
20. Eggstein S, Bashir M, Gao Y, Luo H, Yang X, Zhang Y et al. Resistance to beta-catenin inhibition is mediated by AKT-dependent nuclear factor kappaB pathway. Clin Cancer Res 2011; 17: 4562–4571.
21. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Oncogene (2015) 4914–4927.
MEK-dependent regulation of β-catenin/TCF4 activity
E Lemieux et al

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)